Risa Hoffman is an Infectious Disease physician affiliated with University of California, Los Angeles. OpenAlex indexes 192 publications with 3,284 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Medical Plz
Suite 365 B
Los Angeles, CA 900950001
Telephone
310-206-7663Registry record last updated 30 Dec 2008.
Clinical trials
- Kupewa: Optimizing Implementation Strategies for Cervical Cancer Prevention
Sponsor: New York University
- INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV
Sponsor: University of California, Los Angeles
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.1%Statin38.6%Atorvastatin Calcium55%Rosuvastatin Calcium45%Part D<11 patientsAngiotensin receptor blocker (ARB)10.3%Losartan Potassium100%Part D<11 patients+ 3 more classes in this area
Nervous system
10.9%SSRI10.9%Citalopram Hbr100%Part D<11 patientsRespiratory
10.3%beta2-Adrenergic Agonist10.3%Ventolin Hfa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Preferences and acceptability for long‐acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya
Journal of the International AIDS Society
2023 - Mobility and ART retention among men in Malawi: a mixed‐methods study
Journal of the International AIDS Society
2023 - Experiences with telemedicine for HIV care in two federally qualified health centers in Los Angeles: a qualitative study
BMC Health Services Research
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”